Embolis 2.5/Embolis 5 Adverse Reactions

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing Brand Resources

Full Prescribing Info

Adverse Reactions

Tabulated list of adverse reactions: Table 2 shows the adverse reactions ranked under headings of system organ class and frequency using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data) for VTEp, NVAF, and VTEt respectively. (See Table 2.)

Click on icon to see table/diagram/image

The use of Apixaban Tablets may be associated with an increased risk of occult or overt bleeding from any tissue or organ, which may result in posthaemorrhagic anaemia. The signs, symptoms, and severity will vary according to the location and degree or extent of the bleeding.

View ADR Reporting Link

Embolis 2.5/Embolis 5 Adverse Reactions

apixaban

Manufacturer:

Zydus Healthcare

Distributor:

Zydus Healthcare